Literature DB >> 32448902

Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.

Paul Krogstad1, Pearl Samson2, Edward P Acosta3, Jack Moye4, Ellen Townley5, Sarah Bradford6, Emily Brown6, Kayla Denson7, Bobbie Graham7, Laura Hovind7, Thucuma Sise5, Hedy Teppler8, Sisinyana Ruth Mathiba9, Lee Fairlie10, Jana L Winckler11, Gretchen Slade12, Tammy Meyers13.   

Abstract

Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. CLINICAL TRIALS REGISTRATION: NCT01751568.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antiretroviral therapy; drug interactions; pediatrics; rifampin; tuberculosis

Mesh：

Substances：

Year:  2021        PMID： 32448902      PMCID： PMC7996637          DOI： 10.1093/jpids/piaa039

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  5 in total

1.  Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.

Authors:  Tammy Meyers; Pearl Samson; Edward P Acosta; Jack Moye; Ellen Townley; Sarah Bradford; Linda Marillo; Kayla Denson; Laura Hovind; Thucuma Sise; Hedy Teppler; Sisinyana Ruth Mathiba; Masebole Masenya; Anneke Hesseling; Mark F Cotton; Paul Krogstad
Journal:  AIDS       Date:  2019-11-15       Impact factor: 4.177

2.  Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study.

Authors:  Helena Rabie; Paolo Denti; Janice Lee; Mhleli Masango; Ashraf Coovadia; Sandy Pillay; Afaaf Liberty; François Simon; Helen McIlleron; Mark F Cotton; Marc Lallemant
Journal:  Lancet HIV       Date:  2018-12-06       Impact factor: 12.767

3.  Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.

Authors:  Yuan Ren; James J C Nuttall; Brian S Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen M McIlleron
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-15       Impact factor: 3.731

4.  Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.

Authors:  Larissa A Wenning; William D Hanley; Diana M Brainard; Amelia S Petry; Kalyan Ghosh; Bo Jin; Eric Mangin; Thomas C Marbury; Jolene K Berg; Jeffrey A Chodakewitz; Julie A Stone; Keith M Gottesdiener; John A Wagner; Marian Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

5.  Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.

Authors:  Nilesh B Bhatt; Elisabeth Baudin; Bindiya Meggi; Carlota da Silva; Aurélie Barrail-Tran; Valérie Furlan; Beatriz Grinsztejn; Maryline Bonnet; Anne-Marie Taburet
Journal:  J Antimicrob Chemother       Date:  2014-09-18       Impact factor: 5.790
  5 in total
  1 in total

1.  Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.

Authors:  Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.